Neximmune, yale, and jdrf extend research partnership for type 1 diabetes

Gaithersburg, md., oct. 24, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi) announces the extension of the research partnership between neximmune, yale and jdrf to explore the use of neximmune's aim nanoparticles in combination with an anti-cd3 mab to tolerize, deplete or modulate diabetes antigen-specific t cells. the extension includes an additional $300,000 grant, funded by jdrf to yale, as a part of its cures research portfolio, which includes therapies for the prevention of type 1 diabetes (t1d).
NEXI Ratings Summary
NEXI Quant Ranking